

EMA/202091/2026
Version 1.0

# Programme of the 2026 annual meeting of the European network of paediatric research at EMA (EnprEMA)

## Thursday, 5 November 2026

European Medicines Agency (2C) and online

Image: Adobe Stock

## Background

The European Network of Paediatric Research at the European Medicines Agency (EnprEMA) brings together research networks, investigators and centres with recognised expertise in conducting clinical trials in children. Its main objective is to facilitate high-quality paediatric clinical research and thereby support the development and availability of authorised medicines for children.

The EnprEMA annual meeting provides an opportunity for member networks and other stakeholders involved in paediatric clinical trials, including healthcare professionals, parents, carers, patient representatives, medicine developers and regulators, to exchange views on the network's priority activities. The meeting is intended to strengthen collaboration between networks and stakeholders and to support competence building at European level

## Objectives of the event

The 2026 EnprEMA annual meeting aims to support exchange on priority areas for strengthening paediatric clinical research in Europe. The meeting will focus on advancing platform trial readiness, improving trial infrastructure and methodological approaches, strengthening patient engagement and recruitment facilitation, and discussing regulatory science developments relevant to paediatric drug development.

## Programme

Chairpersons: Ricardo Fernandes and Gunter Egger

| Time | Topic | Topic lead | Duration |
|---|---|---|---|
| 09:00 | *Arrival and registration*<br>*(Virtual meeting room open for remote participants)* | | |
| 09:30 | **Welcome address** | *Ralph Bax* | *5 min* |
| 09:35 | **Opening remarks by EnprEMA Co-chairs** | *Ricardo Fernandes*<br>*Gunter Egger* | *15 min* |
| | **SESSION I – Supporting paediatric drug development through models, biomarkers** | | |
| 09:50 | Disease and progression models to support paediatric drug development | *Cecile Ollivier* | *20 min* |
| 10:10 | Framework for model evaluation and qualification of biomarkers to support paediatric drug development | *Efthymios Manolis* | *20 min* |
| 10:30 | Discussion – Q&A | *Sara Vennberg* | *30 min* |
| 11:00 | **Coffee break** | | *20 min* |
| | **SESSION II – Platform trials: building awareness, capacity and evidence** | | |
| 11:20 | Optimising paediatric academic-industry platform trials: successes, lessons learned and needs | *Pamela Kearns* | *20 min* |

| Time | Topic | Topic lead | Duration |
|---|---|---|---|
| 11:40 | Platform trials to inform paediatric drug development: an industry perspective | *Angeliki Siapkara* | *20 min* |
| 12:00 | Discussion – Q&A | *Dominik Karres* | *30 min* |
| | **RECENT DEVELOPMENTS** | | |
| 12:30 | Update on the assessor's guidance on best practices for paediatric clinical trials | *Monique Al*<br>*Anette Solli Karlsen* | *20 min* |
| 12:50 | **Lunch** | | *60 min* |
| | **SESSION III – Advancing patient partnership and patient experience in paediatric medicines development: from engagement to evidence** | | |
| 13:50 | Current capability: insights from recent PPI surveys | *Ségolène Gaillard*<br>*Maria Mavris* | *20 min* |
| 14:10 | Developments regarding Patient Panels | *Laura Pioppo* | *20 min* |
| 14:30 | Discussion – Q&A | *Tomasz Grybek* | *25 min* |
| 14:55 | **Coffee break** | | *20 min* |
| | **RECENT DEVELOPMENTS** | | |
| 15:15 | Reporting guidelines and paediatric drug development: SPIRIT-C & CONSORT-C | *Martin Offringa* | *20 min* |
| 15:35 | Preparedness for public health emergencies (PHE) | *Laura Fregonese* | *20 min* |
| 15:55 | First-in-child/first-in-human workshop – reporting back | *Gilles Vassal* | *20 min* |
| 16:15 | AOB and conclusions | Ricardo Fernandes<br>Gunter Egger | *15 min* |
| 16:30 | End of the meeting | | |

**List of speakers / chairpersons:**

| Surname | Name | Affiliation |
|---|---|---|
| *Al* | *Monique* | *CCMO - Central Committee on Research Involving Human Subjects, The Netherlands, CTCG – Clinical Trials Coordination Group, MedEthicsEU* |
| *Bax* | *Ralph* | *European Medicines Agency* |
| *Egger* | *Gunter* | *European Medicines Agency, Co-chair of EnprEMA* |
| *Fernandes* | *Ricardo* | *STAND4Kids - Supporting Paediatric Trials in Portugal, Chair of EnprEMA* |
| *Fregonese* | *Laura* | *European Medicines Agency* |
| *Gaillard* | *Ségolène* | *French paediatric research network (Kids France)* |
| *Grybek* | *Tomasz* | *Paediatric Committee (PDCO), EURORDIS – European Organisation for Rare Diseases* |
| *Karres* | *Dominik* | *European Medicines Agency* |
| *Kearns* | *Pamela* | *ITCC - Innovative Therapies for Children with Cancer* |
| *Manolis* | *Efthymios* | *European Medicines Agency* |
| *Mavris* | *Maria* | *European Medicines Agency* |
| *Offringa* | *Martin* | *The Hospital for Sick Children, Canada* |
| *Ollivier* | *Cecile* | *Critical Path Institute (C-Path)* |
| *Pioppo* | *Laura* | *European Medicines Agency* |
| *Siapkara* | *Angeliki* | *EFPIA - European Federation of pharmaceutical Industries and Associations, AstraZeneca* |
| *Solli Karlsen* | *Anette* | *Paediatric Committee (PDCO), Norwegian Medical Products Agency* |
| *Vassal* | *Gilles* | *ITCC - Innovative Therapies for Children with Cancer* |
| *Vennberg* | *Sara* | *Paediatric Committee (PDCO), Swedish Medical Products Agency* |